Narcolepsy - Pipeline Insight, 2018

SKU ID : DEL-

Publishing Date : 07-Mar-2018

No. of pages : 76

PRICE
1250
4000


  • "Narcolepsy - Pipeline Insight, 2018" report by DelveInsight outlays comprehensive Insight of present scenario and growth prospects across Narcolepsy. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 20+ products along with 15+ companies involved.
    Products covered by Phase
    • Phase III, Phase II, Phase I and IND
    • Pre-clinical & Discovery
    • Inactive (Dormant and Discontinued)
    Overview of pipeline development activities for Narcolepsy
    Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
    Therapeutic segmentation of products for Narcolepsy
    The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.
    Methodology
    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
    Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
    Scope of the report
    • Provides an overview of therapeutic pipeline activity for Narcolepsy across the complete product development cycle including all clinical and non-clinical stages
    • It comprises of detailed profiles of Narcolepsy therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
    • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    • Coverage of dormant and discontinued pipeline projects across Narcolepsy

    Reasons to Buy
    • Establish a comprehensive understanding of the current pipeline scenario across Narcolepsy to formulate effective R&D strategies
    • Assess challenges and opportunities that influence Narcolepsy R&D
    • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
    • Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
    • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Narcolepsy to enhance and expand business potential and scope
    • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

























































    Detailed TOC of Narcolepsy - Pipeline Insight, 2018

    Overview
    Types of Narcolepsy
    Epidemiology
    Causes
    Symptoms
    Pathophysiology
    Diagnosis
    Treatment
    Pipeline Therapeutics
    Competitive Landscape
    Comparative Analysis
    Late Stage Products (Phase III)
    Comparative Analysis
    Solriamfetol: Jazz Pharmaceuticals
    Product Description
    Research and Development
    Product Development Activities
    (The list continues)
    Mid Stage Products (Phase II)
    Comparative Analysis
    Early Stage Products (Phase I and IND)
    Comparative Analysis
    Pre-clinical and Discovery Products
    Comparative Analysis
    Therapeutic Assessment
    Assessment by Product Type
    Assessment by Route of Administration
    Assessment by Stage and Route of Administration
    Dormant and Discontinued Products
    Comparative Analysis
    Appendix

    List of Figures, Tables and Charts Available in Narcolepsy - Pipeline Insight, 2018

    Table 1: Total Products for Narcolepsy
    Table 2: Late Stage Products (Phase III)
    Table 3: Mid Stage Products (Phase II)
    Table 4: Early Stage Products (Phase I and IND)
    Table 5: Pre-clinical and Discovery Stage Products
    Table 6: Assessment by Mono Products
    Table 7: Assessment by Combination Products
    Table 8: Assessment by Route of Administration
    Table 9: Assessment by Stage and Route of Administration
    Table 10: Dormant Products
    Table 11: Discontinued Products

    Figure 1: Pathophysiology of Narcolepsy
    Figure 2: Total Products for Narcolepsy
    Figure 3: Late Stage Products (Phase III)
    Figure 4: Mid Stage Products (Phase II)
    Figure 5: Early Stage Products (Phase I and IND)
    Figure 6: Pre-clinical and Discovery Stage Products
    Figure 7: Assessment by Product Type
    Figure 8: Assessment by Route of Administration
    Figure 9: Assessment by Stage and Route of Administration
    Figure 10: Dormant and Discontinued Products

    Keyplayers in Narcolepsy - Pipeline Insight, 2018

    Arena Pharmaceuticals
    Avadel Pharmaceuticals
    Balance Therapeutics
    Evotec AG
    GlaxoSmithKline
    Heptares Therapeutics
    Jazz Pharmaceuticals
    Johnson & Johnson
    NLS Pharma
    Ono Pharmaceutical
    OptiNose
    Pfizer
    Reset Therapeutics
    Roche
    Sanofi
    Seelos Therapeutics
    Taisho Pharmaceutical
    Takeda
    Theranexus